1. Home
  2. IVA vs RMNI Comparison

IVA vs RMNI Comparison

Compare IVA & RMNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IVA
  • RMNI
  • Stock Information
  • Founded
  • IVA 2011
  • RMNI 2005
  • Country
  • IVA France
  • RMNI United States
  • Employees
  • IVA N/A
  • RMNI N/A
  • Industry
  • IVA Biotechnology: Pharmaceutical Preparations
  • RMNI Business Services
  • Sector
  • IVA Health Care
  • RMNI Consumer Discretionary
  • Exchange
  • IVA Nasdaq
  • RMNI Nasdaq
  • Market Cap
  • IVA 359.6M
  • RMNI 368.8M
  • IPO Year
  • IVA 2020
  • RMNI N/A
  • Fundamental
  • Price
  • IVA $2.97
  • RMNI $4.68
  • Analyst Decision
  • IVA Strong Buy
  • RMNI Buy
  • Analyst Count
  • IVA 4
  • RMNI 2
  • Target Price
  • IVA $10.50
  • RMNI $6.00
  • AVG Volume (30 Days)
  • IVA 15.3K
  • RMNI 523.9K
  • Earning Date
  • IVA 09-24-2025
  • RMNI 07-31-2025
  • Dividend Yield
  • IVA N/A
  • RMNI N/A
  • EPS Growth
  • IVA N/A
  • RMNI N/A
  • EPS
  • IVA N/A
  • RMNI N/A
  • Revenue
  • IVA $14,591,573.00
  • RMNI $426,212,000.00
  • Revenue This Year
  • IVA $15.38
  • RMNI $1.38
  • Revenue Next Year
  • IVA $24.22
  • RMNI $3.97
  • P/E Ratio
  • IVA N/A
  • RMNI N/A
  • Revenue Growth
  • IVA N/A
  • RMNI N/A
  • 52 Week Low
  • IVA $1.53
  • RMNI $1.53
  • 52 Week High
  • IVA $4.05
  • RMNI $5.38
  • Technical
  • Relative Strength Index (RSI)
  • IVA 38.99
  • RMNI 58.96
  • Support Level
  • IVA $3.12
  • RMNI $4.60
  • Resistance Level
  • IVA $3.61
  • RMNI $4.80
  • Average True Range (ATR)
  • IVA 0.24
  • RMNI 0.25
  • MACD
  • IVA -0.01
  • RMNI -0.05
  • Stochastic Oscillator
  • IVA 13.95
  • RMNI 53.64

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

About RMNI Rimini Street Inc. (DE)

Rimini Street Inc and its subsidiaries are providers of end-to-end enterprise software support, products, and services. The Company offers a comprehensive family of unified solutions to run, manage, support, customize, configure, connect, protect, monitor, and optimize clients' enterprise applications, database, and technology software platforms. The Company derives revenues from clients by providing subscription support services for enterprise resource planning, customer relationship management, product lifecycle management database, and technology software systems. Geographically, the company generates the majority of its revenue from the United States of America and the International market.

Share on Social Networks: